ImmuneSpec — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Founded in 2017 and based in Leuven, Belgium, ImmuneSpec is a specialized service provider in the immunopeptidomics space. The company leverages a proprietary, high-sensitivity platform to identify peptides presented by MHC molecules, offering crucial insights for biotherapeutic developers in immunogenicity testing, vaccine design, and cancer immunotherapy target validation. As a private, likely pre-revenue or early-revenue company, ImmuneSpec operates on a B2B service model, partnering with pharmaceutical and biotech clients to de-risk and accelerate their R&D pipelines through precise, data-driven epitope mapping.

ImmunologyInfectious DiseaseOncology

Technology Platform

Proprietary high-sensitivity immunopeptidomics (MAPPs) platform utilizing advanced mass spectrometry and bioinformatics to identify and quantify peptides presented by MHC molecules.

Opportunities

The rapid growth in biotherapeutics, personalized cancer vaccines, and novel vaccine platforms creates a strong demand for precise immunogenicity and antigen presentation data.

ImmuneSpec's high-sensitivity service model is well-positioned to become an essential partner for biotech and pharma companies seeking to de-risk clinical development and improve therapeutic efficacy.

Risk Factors

Key risks include slower-than-expected adoption of immunopeptidomics in standard drug development workflows, competition from in-house capabilities at large pharma or alternative prediction tools, and the operational challenge of scaling a high-quality, capital-intensive service business while maintaining rapid turnaround times.

Competitive Landscape

ImmuneSpec competes with other specialized CROs offering MAPPs services, internal capabilities at large pharmaceutical companies, and bioinformatics firms providing in silico T-cell epitope prediction tools. Its claimed differentiation is based on superior analytical sensitivity, a client-centric service model, and deep expertise in peptidomics.

More companies in Proteomics & Protein Engineering →More companies in Belgium →